- Home
- LSF vs NRXP Comparison
LSF vs NRXP Comparison
Compare LSF & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 63.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | NRXP |
|---|---|---|
| Price | $2.26 | $2.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $30.50 |
| AVG Volume (30 Days) | 88.3K | ★ 455.8K |
| Earning Date | 11-10-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $242,000.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.13 | $1.15 |
| 52 Week High | $8.96 | $6.01 |
Technical Indicators
Market Signals| Indicator | LSF | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 41.12 |
| Support Level | $2.13 | $2.22 |
| Resistance Level | $2.52 | $2.39 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 18.94 | 38.89 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.